MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Perrigo Company plc Retained Earnings 2011-2026 | PRGO
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Perrigo Company plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.68 B | -2.25 B | -2.08 B | -2.07 B | -1.93 B | -1.86 B | -1.7 B | -1.84 B | -1.98 B | -2.1 B | 1.94 B | 1.88 B | 1.72 B | 1.31 B | 934 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.94 B | -3.68 B | -913 M |
Quarterly Retained Earnings Perrigo Company plc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.26 B | -2.27 B | -2.26 B | -2.25 B | -2.21 B | -2.19 B | -2.08 B | -2.08 B | -2.05 B | -2.06 B | -2.07 B | -2.07 B | -2.04 B | -1.99 B | -1.93 B | -1.93 B | -1.94 B | -1.88 B | -1.82 B | -1.86 B | -1.86 B | -1.86 B | -1.86 B | -1.7 B | -1.7 B | -1.7 B | -1.7 B | -1.84 B | -1.84 B | -1.84 B | -1.84 B | -1.98 B | -1.98 B | -1.98 B | -1.98 B | -2.1 B | -2.1 B | -2.1 B | -2.1 B | 1.98 B | 1.98 B | 1.98 B | 1.98 B | 2.01 B | 1.96 B | 1.9 B | 1.96 B | 1.72 B | -191 K | 1.72 B | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.01 B | -2.27 B | -1.16 B |
Retained Earnings of other stocks in the Drug manufacturers industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
-1.15 B | - | - | $ 754 M |  USA |
 |
Alimera Sciences
ALIM
|
-418 M | - | - | $ 142 M | USA |
 |
Canopy Growth Corporation
CGC
|
-10.9 B | $ 1.05 | -3.24 % | $ 113 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-457 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-305 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
-423 M | - | 10.11 % | $ 58.2 M | USA |
 |
Harrow Health
HROW
|
-157 M | $ 36.88 | -5.98 % | $ 1.36 B | USA |
 |
Cronos Group
CRON
|
1.06 B | $ 2.6 | -0.76 % | $ 1.36 B | Canada |
 |
Catalent
CTLT
|
-781 M | - | - | $ 11.5 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-794 M | - | - | $ 2.06 B |  France |
 |
Evolus
EOLS
|
-661 M | $ 5.74 | 2.68 % | $ 370 M | USA |
 |
China Pharma Holdings
CPHI
|
-44 M | $ 0.59 | 1.55 % | $ 10.3 M |  China |
 |
DURECT Corporation
DRRX
|
-589 M | - | - | $ 50.1 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-24 M | $ 3.62 | -1.36 % | $ 50.9 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
112 M | - | -39.89 % | $ 27.7 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-1.43 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Endo International plc
ENDP
|
-15.4 B | - | - | $ 28.9 M |  Irlanda |
 |
HEXO Corp.
HEXO
|
-659 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Evoke Pharma
EVOK
|
-123 M | - | - | $ 36.6 M | USA |
 |
Aurora Cannabis
ACB
|
-3.59 B | $ 3.56 | -2.47 % | $ 86.3 M | Canada |
 |
Athenex
ATNX
|
-1.02 B | - | -23.39 % | $ 1.76 M | USA |
 |
OrganiGram Holdings
OGI
|
-145 M | $ 1.47 | 5.4 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
-40.1 M | $ 2.98 | 4.01 % | $ 392 M | USA |
 |
Jupiter Wellness
JUPW
|
-115 M | - | - | $ 33.6 M | USA |
 |
Emergent BioSolutions
EBS
|
-21.8 M | $ 8.46 | -3.53 % | $ 433 M | USA |
 |
Assertio Holdings
ASRT
|
-652 M | $ 11.9 | -1.41 % | $ 845 M | USA |
 |
Bausch Health Companies
BHC
|
-9.78 B | $ 5.61 | -0.44 % | $ 2.05 B | Canada |
 |
Sundial Growers
SNDL
|
-565 M | $ 1.54 | -0.09 % | $ 3.37 M | Canada |
 |
Lannett Company
LCI
|
-596 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-187 M | - | - | $ 193 M | Canada |
 |
TherapeuticsMD
TXMD
|
-950 M | $ 2.21 | 2.3 % | $ 23.1 M | USA |
 |
Veru
VERU
|
-295 M | $ 2.5 | -0.4 % | $ 337 M | USA |
 |
ProPhase Labs
PRPH
|
11.8 M | - | - | $ 5.07 M | USA |
 |
Viatris
VTRS
|
5.18 B | $ 14.57 | -0.95 % | $ 17.5 B | USA |
 |
Radius Health
RDUS
|
-1.37 B | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
-397 M | $ 0.88 | -1.22 % | $ 20.5 M | USA |
 |
Pacira BioSciences
PCRX
|
-206 M | $ 22.97 | 0.48 % | $ 1.06 B | USA |
 |
PetIQ
PETQ
|
-161 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
-720 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-148 M | - | -27.8 % | $ 2.56 M | USA |
 |
cbdMD
YCBD
|
-182 M | $ 0.75 | -2.34 % | $ 3.23 M | USA |
 |
Recro Pharma
REPH
|
-279 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
-561 M | $ 4.3 | -9.85 % | $ 129 M | USA |
 |
SCYNEXIS
SCYX
|
-385 M | $ 0.76 | -1.66 % | $ 37.9 M | USA |
 |
Solid Biosciences
SLDB
|
-783 M | $ 5.76 | -6.19 % | $ 235 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-198 M | $ 2.63 | -6.07 % | $ 3.26 M | USA |
 |
Tricida
TCDA
|
-810 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-2.42 B | $ 7.1 | -2.79 % | $ 4.39 B | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
-275 M | - | - | $ 55.5 M | USA |